Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity

Giulia Pinton, Arcangela G. Manente, Antonio Daga, Michele Cilli, Maurizio Rinaldi, Stefan Nilsson, Laura Moro

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Estrogen receptor (ER) β acts as a tumor suppressor in malignant mesotheliomas.Methods: Here we explored the anti-proliferative and anti-tumorigenic efficacy of the selective ERβ agonist, KB9520, in human mesothelioma cell lines in vitro and in a mesothelioma mouse model in vivo.Results: KB9520 showed significant anti-proliferative effect in ERβ positive human malignant pleural mesothelioma cells in vitro. Selective activation of ERβ with KB9520 sensitized the cells to treatment with cisplatin, resulting in enhanced growth inhibition and increased apoptosis. Furthermore, in CD1 nude mice mesothelioma tumor growth was significantly inhibited when KB9520 was added on top of the standard of care chemo combination cisplatin/pemetrexed, as compared to the cisplatin/pemetrexed alone group. Importantly, KB9520 exerted a protective effect to cisplatin toxicity in the non-malignant mesothelium derived MET5A cells.Conclusions: Together, the data presented suggest that selective targeting of ERβ may be an efficacious stand-alone treatment option and/or become an important add-on to existing malignant mesothelioma therapy.

Original languageEnglish
Article number227
JournalMolecular Cancer
Volume13
Issue number1
DOIs
Publication statusPublished - Oct 2 2014

Fingerprint

Estrogen Receptor beta
Cisplatin
Pemetrexed
Mesothelioma
Standard of Care
Growth
Nude Mice
Estrogen Receptors
Neoplasms
Estrogens
Epithelium
Apoptosis
Cell Line
Malignant Mesothelioma
In Vitro Techniques
Therapeutics

Keywords

  • Cisplatin
  • Estrogen Receptor β
  • Malignant mesothelioma
  • Receptor agonist
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology

Cite this

Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. / Pinton, Giulia; Manente, Arcangela G.; Daga, Antonio; Cilli, Michele; Rinaldi, Maurizio; Nilsson, Stefan; Moro, Laura.

In: Molecular Cancer, Vol. 13, No. 1, 227, 02.10.2014.

Research output: Contribution to journalArticle

Pinton, Giulia ; Manente, Arcangela G. ; Daga, Antonio ; Cilli, Michele ; Rinaldi, Maurizio ; Nilsson, Stefan ; Moro, Laura. / Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. In: Molecular Cancer. 2014 ; Vol. 13, No. 1.
@article{c7dd4e08f65f4556afb490a163cb82d2,
title = "Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity",
abstract = "Background: Estrogen receptor (ER) β acts as a tumor suppressor in malignant mesotheliomas.Methods: Here we explored the anti-proliferative and anti-tumorigenic efficacy of the selective ERβ agonist, KB9520, in human mesothelioma cell lines in vitro and in a mesothelioma mouse model in vivo.Results: KB9520 showed significant anti-proliferative effect in ERβ positive human malignant pleural mesothelioma cells in vitro. Selective activation of ERβ with KB9520 sensitized the cells to treatment with cisplatin, resulting in enhanced growth inhibition and increased apoptosis. Furthermore, in CD1 nude mice mesothelioma tumor growth was significantly inhibited when KB9520 was added on top of the standard of care chemo combination cisplatin/pemetrexed, as compared to the cisplatin/pemetrexed alone group. Importantly, KB9520 exerted a protective effect to cisplatin toxicity in the non-malignant mesothelium derived MET5A cells.Conclusions: Together, the data presented suggest that selective targeting of ERβ may be an efficacious stand-alone treatment option and/or become an important add-on to existing malignant mesothelioma therapy.",
keywords = "Cisplatin, Estrogen Receptor β, Malignant mesothelioma, Receptor agonist, Therapy",
author = "Giulia Pinton and Manente, {Arcangela G.} and Antonio Daga and Michele Cilli and Maurizio Rinaldi and Stefan Nilsson and Laura Moro",
year = "2014",
month = "10",
day = "2",
doi = "10.1186/1476-4598-13-227",
language = "English",
volume = "13",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity

AU - Pinton, Giulia

AU - Manente, Arcangela G.

AU - Daga, Antonio

AU - Cilli, Michele

AU - Rinaldi, Maurizio

AU - Nilsson, Stefan

AU - Moro, Laura

PY - 2014/10/2

Y1 - 2014/10/2

N2 - Background: Estrogen receptor (ER) β acts as a tumor suppressor in malignant mesotheliomas.Methods: Here we explored the anti-proliferative and anti-tumorigenic efficacy of the selective ERβ agonist, KB9520, in human mesothelioma cell lines in vitro and in a mesothelioma mouse model in vivo.Results: KB9520 showed significant anti-proliferative effect in ERβ positive human malignant pleural mesothelioma cells in vitro. Selective activation of ERβ with KB9520 sensitized the cells to treatment with cisplatin, resulting in enhanced growth inhibition and increased apoptosis. Furthermore, in CD1 nude mice mesothelioma tumor growth was significantly inhibited when KB9520 was added on top of the standard of care chemo combination cisplatin/pemetrexed, as compared to the cisplatin/pemetrexed alone group. Importantly, KB9520 exerted a protective effect to cisplatin toxicity in the non-malignant mesothelium derived MET5A cells.Conclusions: Together, the data presented suggest that selective targeting of ERβ may be an efficacious stand-alone treatment option and/or become an important add-on to existing malignant mesothelioma therapy.

AB - Background: Estrogen receptor (ER) β acts as a tumor suppressor in malignant mesotheliomas.Methods: Here we explored the anti-proliferative and anti-tumorigenic efficacy of the selective ERβ agonist, KB9520, in human mesothelioma cell lines in vitro and in a mesothelioma mouse model in vivo.Results: KB9520 showed significant anti-proliferative effect in ERβ positive human malignant pleural mesothelioma cells in vitro. Selective activation of ERβ with KB9520 sensitized the cells to treatment with cisplatin, resulting in enhanced growth inhibition and increased apoptosis. Furthermore, in CD1 nude mice mesothelioma tumor growth was significantly inhibited when KB9520 was added on top of the standard of care chemo combination cisplatin/pemetrexed, as compared to the cisplatin/pemetrexed alone group. Importantly, KB9520 exerted a protective effect to cisplatin toxicity in the non-malignant mesothelium derived MET5A cells.Conclusions: Together, the data presented suggest that selective targeting of ERβ may be an efficacious stand-alone treatment option and/or become an important add-on to existing malignant mesothelioma therapy.

KW - Cisplatin

KW - Estrogen Receptor β

KW - Malignant mesothelioma

KW - Receptor agonist

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84908094913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908094913&partnerID=8YFLogxK

U2 - 10.1186/1476-4598-13-227

DO - 10.1186/1476-4598-13-227

M3 - Article

C2 - 25277603

AN - SCOPUS:84908094913

VL - 13

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 227

ER -